TrimRx vs MEDVi (2026): Two GLP-1 Pricing Models Compared

What TrimRx and MEDVi each are

A quick disambiguation, because the names cause real confusion: TrimRx is not Trimi. They are separate, unaffiliated companies with different pricing, pharmacies, and provider networks — our TrimRx vs Trimi comparison covers that pairing in detail. This page compares TrimRx against MEDVi, the matchup people searching both brands actually want.

Both platforms are established players. MEDVi's own site claims more than 500,000 patients, and TrimRx was reviewed by U.S. News & World Report in June 2026, which credited it with fast onboarding — medication in about five to seven days for most patients — while noting slow customer service as its main weakness. Both companies describe legitimate clinical structures: an online intake, an asynchronous review by a licensed provider, and a prescription only when treatment is clinically appropriate. If you want the deeper single-provider write-ups, see is TrimRx legit and is MEDVi legit.

TrimRx vs MEDVi vs Trimi: side-by-side

Pricing below reflects each provider's public pages and recent third-party checks as of August 2026. TrimRx's per-medication prices load inside its intake flow, so its figures are the most likely to have shifted — treat them as a model, and confirm the exact number at checkout.

Neither TrimRx nor MEDVi advertises a separate membership fee on compounded plans; MEDVi's brand-name routes use a separate membership-plus-medication structure. All three programs require a prescription from a licensed provider, and pricing at every provider only matters if a provider determines treatment is appropriate for you.

TrimRx's model: prepaid bundles that reward commitment upfront

TrimRx's public pricing page advertises plans from $179/month, and independent pricing checks through mid-2026 consistently describe the same structure: single-month rates near $199/month for injectable compounded semaglutide and near $349/month for injectable tirzepatide, with 3-, 6-, and 12-month bundles that bring the effective monthly rate down — into the $170s for semaglutide and the $280s for tirzepatide on 12-month terms. Oral formats are priced slightly below their injectable counterparts.

The detail that matters most is how bundles are billed: multi-month plans are charged upfront in full when the prescription is approved. A 12-month semaglutide bundle is a four-figure charge on day one. That structure genuinely lowers the per-month cost for patients certain they will complete the plan, but third-party reviews note a recurring complaint pattern around unexpected multi-month charges and cancellation friction, and TrimRx's Trustpilot rating sat near 3.2–3.3 stars in 2026 checks. Read the refund terms before the first charge, not after.

Two more things worth knowing. First, TrimRx displays a LegitScript seal on its site — a meaningful verification signal in this category, and one you can confirm directly through LegitScript's checker. Second, TrimRx does not name its partner compounding pharmacy on its public pages, so ask which state-licensed pharmacy will prepare your prescription before you pay. Our TrimRx review and TrimRx cost guide cover the program in more depth.

MEDVi's model: a discounted first month, then the refill rate

MEDVi prices the opposite way. Instead of asking for months upfront, it discounts month one: compounded semaglutide injections start at $179 for the first month on MEDVi's own landing page in our August 2026 check — with $149 introductory offers reported by third-party reviews the same month — with no contract and free shipping. After the first month, 2026 pricing checks consistently list semaglutide refills at $299/month, a rate they describe as locked rather than rising with dose. The same checks put tirzepatide injections at $279 for the first month with ongoing rates reported at $399–$499/month depending on dose, and dissolvable GLP-1 tablets at $249. MEDVi's own pages carry the model's outline — a discounted start, no membership or hidden fees, and a money-back guarantee — but per-medication refill rates were not published on the public pages we checked, so confirm your exact rate before paying.

The refill rate, not the first-month rate, is the number to compare, because GLP-1 treatment is long-term: at listed rates, a first year of MEDVi semaglutide runs roughly $3,400–$3,470 ($149 or $179 plus eleven refills at $299) — and third-party checks note MEDVi renews on 28-day cycles rather than calendar months, so a full year can include a thirteenth cycle. To MEDVi's credit, its structure is clean about what it excludes: compounded plans advertise no membership or hidden fees, the plan price covers the provider review, treatment plan, medication, and shipping, and HSA/FSA payment is accepted. Prescriptions are issued only after a consultation with an independent licensed provider — MEDVi works with provider networks including OpenLoop Health — and its pages state plainly that compounded medications are prepared by state-licensed pharmacies and are not FDA-approved.

MEDVi is month-to-month with no contract, which makes it the lower-risk way to start — and the more expensive way to continue. For the deeper breakdowns, see our MEDVi cost guide and MEDVi alternatives pages.

The third option: Trimi's flat annual pricing

Trimi (founded May 2024, headquartered in New York City) removes the month-one-versus-refills math entirely. Compounded semaglutide is $99/month and compounded tirzepatide is $125/month on the annual plan — the same price in month one and month twelve, and the same price at every prescribed dose. The monthly number includes the medication, evaluation and ongoing care from a licensed provider in the Arora Health 50-state network, and free next-day-air shipping — once prescribed, medication typically arrives within 36 hours.

The honest trade-off: Trimi's $99/$125 rates belong to the annual plan, which is a 12-month commitment backed by a 6-month money-back promise — not cancel-anytime billing. Patients who want to test GLP-1 treatment for a single month will find MEDVi's no-contract first month a better fit for that specific goal. Patients planning a sustained course of treatment — which is how these medications are designed to be used — keep more money with a flat rate than with either an intro-then-refill or a prepaid-bundle structure. Compounded preparations at every provider in this comparison are prepared per individual prescription by a state-licensed pharmacy and are not FDA-approved as drugs; a licensed provider decides whether treatment is appropriate for you.

For wider context on what the whole market charges, our compounded semaglutide cost guide and compounded tirzepatide cost guide break down the four billing models used across US telehealth — and if you are already on treatment with TrimRx or MEDVi, switching GLP-1 providers without a refill gap is straightforward.

What the medication does — wherever you get it

The clinical evidence behind these programs comes from trials of the FDA-approved products. In the STEP 1 trial, semaglutide 2.4 mg weekly produced an average 14.9% body-weight reduction over 68 weeks alongside lifestyle changes (Wilding et al., New England Journal of Medicine, 2021). In SURMOUNT-1, tirzepatide produced an average 20.9% reduction at the highest dose over 72 weeks (Jastreboff et al., NEJM, 2022). Compounded preparations have not been studied in trials of their own, and individual results vary.

That is also why the FDA's guidance matters when comparing providers: per the FDA, compounded drugs are not reviewed for safety, effectiveness, or quality before marketing, and the agency's alert on unapproved GLP-1 drugs had logged 990 adverse event reports associated with compounded semaglutide as of May 31, 2026. The practical takeaway is not to avoid compounded treatment — it is to choose programs, like the three compared here, where a licensed provider prescribes and a verifiable state-licensed pharmacy prepares each prescription.

Five questions to ask TrimRx or MEDVi before you pay

Which should you choose?

Frequently asked questions